TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 62.2%

Neg 0% Neu 0% Pos 62.2%

TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.